Once versus twice daily formoterol via Novolizer® for patients with moderate to severe COPD-A double-blind, randomised, controlled trial

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 4-13

  Welte, T ^a   Metzenauer, P ^b   Hartmann, U ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Astellas Pharma GmbH   (Germany)

Author keywords

COPD; Formoterol; Once daily; Therapy

Indexed keywords

FENOTEROL PLUS IPRATROPIUM BROMIDE; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSIVE CRISIS; INHALER; INSOMNIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE SPASM; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SHOCK; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYMPTOM; TACHYCARDIA; TREATMENT DURATION; TREMOR;

ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS;

EID: 38049005297     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.09.002     Document Type: Article

References (21)

1. Aalbers R., Ayres J., Backer V., et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19 (2002) 936-943
2. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
3. Rossi A., Kristufek P., Levine B.E., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
4. Vervloet D., Ekstrom T., Pela R., et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 92 (1998) 836-842
5. Maesen B.L., Westermann C.J., Duurkens V.A., et al. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 13 (1999) 1103-1108
6. George J., Kong D.C., Thoman R., et al. Factors associated with medication nonadherence in patients with COPD. Chest 128 (2005) 3198-3204
7. Balkrishnan R., and Christensen D.B. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. Clin Ther 22 (2000) 452-469
8. Sackett D.L., and Haynes R.B. Compliance with Therapeutic Regimens (1976), John Hopkins University Press, Baltimore, MD
9. Rand C.S. Patient adherence with COPD therapy. Eur Respir Rev 14 (2006) 97-101
10. Ryan G.W., and Wagner G.J. Pill taking 'routinization': a critical factor to understanding episodic medication adherence. AIDS Care 15 (2003) 795-806
11. Global Initiative for Chronic Obstructive Lung Disease. 〈www.goldcopd.org〉.
12. Muehlig S., and Petermann F. Krankheitsspezifische Erhebungsverfahren zur Lebensqualität bei Patienten mit Asthma und chronisch- obstruktiver Bronchitis: Hinweise auf Bewertungsinstrumente zur Qualitätssicherung in der Rehabilitation. Die Rehabilitation 37 (1998) Blatt 15
13. Jones P.W., Quirk F.H., and Baveystock C.M. The St. George's Respiratory Questionnaire. Respir Med 85 Suppl. B (1991) 25-31
14. van Noord J.A., Aumann J.L., Janssens E., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
15. Tashkin D.P., and Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 125 (2004) 249-259
16. Cazzola M., Noschese P., Salzillo A., et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
17. Buhl R., Creemers J.P., Vondra V., et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97 (2003) 323-330
18. Boyd G., Morice A.H., Pounsford J.C., et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10 (1997) 815-821
19. Nelson H.S., Weiss S.T., Bleedker E.R., et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
20. Martinez F.D. Safety of long-acting beta-agonists-an urgent need to clear the air. N Engl J Med 353 (2005) 2637-2639
21. Cazzola M., Imperatore, Salzillo A., et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 114 (1998) 411-415